Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03121586 · ClinicalTrials.gov registry record · Phase 3
Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia
A Phase 3 study, sponsored by ACADIA Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 995
- Enrollment target
NCT03121586 is a Phase 3 study that was terminated before completion, run by ACADIA Pharmaceuticals. The registered enrollment target is 995 participants.
The verdict
NCT03121586, a Phase 3 study, was terminated before completion, sponsored by ACADIA Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 995 participants
- Enrollment target
Study Summary
To evaluate the long-term safety and tolerability of pimavanserin after 52 weeks of adjunctive treatment in subjects with schizophrenia
Interventions
- DRUG Pimavanserin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 995 participants |
| Start Date | 2017-01 |
| Est. Completion | 2024-05-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03121586
The ClinicalTrials.gov registry entry for NCT03121586 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 995 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ACADIA Pharmaceuticals, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pimavanserin is the first listed.
NCT03121586 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03121586 about?
NCT03121586 is a clinical study titled "Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia". To evaluate the long-term safety and tolerability of pimavanserin after 52 weeks of adjunctive treatment in subjects with schizophrenia
What is the current status of trial NCT03121586?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 995 participants. The study started on 2017-01. Estimated completion is 2024-05-30.
What interventions are being tested in trial NCT03121586?
The interventions under investigation include: Pimavanserin (DRUG).
Who is sponsoring clinical trial NCT03121586?
This trial is sponsored by ACADIA Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.